Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Impact of Peripheral Blood Lymphocytes on clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

NCT06805812 is registered in ClinicalTrials.gov with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano as lead sponsor.

NCT NCT06805812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06805812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Impact of Peripheral Blood Lymphocytes on clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase
Observational
Overall status
Recruiting
Start date
May 1, 2023
Completion date
December 31, 2040
Enrollment
3,500 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

abemaciclib, breast adenocarcinoma, breast cancer, breast cancer stage iv, breast cancer with metastatic bone disease, breast cancer, metastatic, breast cancers, breast carcinoma, breast diseases, breast neoplasm, breast neoplasms, breast neoplasms, male, breast tumors, cdk4/6 inhibitor, cdk4/6 inhibitors, hormone receptor (hr)-positive breast cancer, hormone receptor negative breast cancer, hormone receptor positive (er+/pr+, and her2-) metastatic breast cancer, hormone receptor positive (hr+), her2-negative breast cancer, hormone receptor positive breast adenocarcinoma, hormone receptor positive breast cancer, hormone receptor positive breast carcinoma, hormone receptor positive breast neoplasms, hormone receptor positive her-2 negative breast cancer, hormone receptor positive malignant neoplasm of breast, hormone receptor positive metastatic breast cancer, hormone receptor positive, her2 negative breast cancer, hormone receptor positive, her2-low neoplasms, hormone receptor positive, her2-negative neoplasms, hormone receptor positive, her2-negative, advanced breast cancer, hormone receptor-positive breast cancer, hormone receptor-positive, her2-negative metastatic breast cancer, hr+ advanced or metastatic breast cancer, hr+ her2- men, pre/postmenopausal advanced breast cancer, hr+/her2- breast cancer, hr-positive breast cancer, hr-positive, her2-negative advanced breast cancer, hr-positive, her2-negative and pik3ca mutation advanced breast cancer, hrpos breast neoplasms, palbociclib, ribociclib